The Government of India Enterprise’s Biotechnology Research wing has selected Optra Scan digital pathology system for its 10,000 patient study.
The study is being carried out to enhance diagnostics techniques and improve treatment options through the adoption of innovative technologies.
World Health Organization (WHO) said that there are around 2.4 million cancer cases in India, as a result of a paradigm shift in the disease pattern from communicable to non-communicable disease, like cancer, diabetes and hypertension.
To support the study, Optra Scan system will be installed for automated digital pathology in over nine large institutions across India, including hospitals and laboratories.
Optra Scan system offers a comprehensive and affordable end-to-end digital pathology solution for effective capturing, viewing, analysis and management of digital slides and associated metadata.
Optra Systems founder and CEO Abhi Gholap said: Digital Pathology systems typically cost anywhere between $100k to $300k, compared to $5k microscopy systems – this remained a big hurdle for adoption. In emerging markets like India, China, South Africa etc. such exorbitant costs are forcing pathologists to still use age old microscopes."
Optra Scan suite includes TMA Scan software for the analysis of tissue microarrays (TMAs), as well as rare event detection algorithms for finding metastasizing cancer cells in blood and locating metaphase-spreads in amniocentesis and bone-marrow specimens analysis algorithms for quantitative analysis of immunohistochemistry (IHC) assays.
The suite also includes image analysis algorithms for quantitative analysis of IHC assays, including ER, PR, Ki 67, Her-2 Neu expression for breast & prostate cancer.
In addition, the suite is comprised of Optra IMAGE Path , Optra Assay , Cloud Path and Optra Tele Path to store, analyze, manage, conference, share and view high resolution whole slide images.
Image: Optra Scan digital pathology scanner. Photo: courtesy of Business Wire.